Community-Based Model for Delivery of Antiretroviral Therapy in Cambodia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04766710 |
|
Recruitment Status :
Recruiting
First Posted : February 23, 2021
Last Update Posted : September 1, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The community-based ART delivery (CAD) model will build on the existing framework to engage community action, operationalized in the current Global Fund-supported project. Community Action Workers (CAW), who are assigned to ART centers and conduct outreach work, are well-suited to administer CAD scheme. KHANA and the project partners all have implementation roles in the Global Fund-supported project and established working channels with the CAW.
While the previous experiences suggest the CAD model's effectiveness, implementing it in Cambodia requires adaptation to its specific local context. The proposed project will be implemented as an implementation study in nine ART sites and supported by a concrete evaluation plan. KHANA Center for Population Health Research will lead the research component.
The project has three strategic areas and corresponding deliverables as follows:
A. The development of a locally-fitted model: bringing ART closer to the people living with HIV B. The research: formulation, evaluation, documentation, and dissemination of the evidence, knowledge, and lessons learned C. The scale-up: advocacy for the SOP development to replicate/scale-up the CAD model
The project will benefit a wide range of stakeholders. The approximately 2,000 ART clients enrolled in the nine selected clinics will face less cost, time, and discrimination, which will also benefit their families. The clinics will have a reduced workload on site, and they would be able to improve the quality of care for the visiting clients. The Cambodian health system will obtain a CAD model tailored to the country's local context and develop Standard Operating Procedures for the scheme with readily involved stakeholders. The scale-up of the model will benefit all other ART clinics and clients in the country.
The 36-months project starting from June 1, 2019, will include six months of start-up and baseline assessments, 24-month intervention, and six-month evaluation.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections AIDS | Other: Community-based ART delivery (CAD) Other: ART multi-month dispensing (MMD) | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 4000 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This quasi-experimental study will consist of two arms. People living with HIV in the intervention arm will receive services from the CAD model, and those in the control arm will receive the standard prevention, care, and support services. The investigators will compare the outcome between these two arms. |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | Project coordinators and people living with HIV in the selected operational districts will not be masked to the intervention. However, all activities will be done without reference to the intervention group. The data analysts will be masked to intervention allocation and will only analyze de-identified data. |
| Primary Purpose: | Health Services Research |
| Official Title: | Implementation and Evaluation of a Community-Based Model for Delivery of Antiretroviral Therapy in Cambodia: A Quasi-Experimental Study |
| Actual Study Start Date : | April 1, 2021 |
| Estimated Primary Completion Date : | March 31, 2023 |
| Estimated Study Completion Date : | March 31, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Community-based ART delivery (CAD)
The CAD model intervention will take place for 24 months. A total of 2000 registered stable people living with HIV will form into the CAD group. The investigators have developed the implementation guide, monitoring tools, quality assurance checklist, and lists of people living with HIV in selected ART clinics for the CAD model intervention. The first step will be to extract the data disaggregated by gender, age, and type of sub-populations, including adolescents, female entertainment workers, men who have sex with men, transgender women, and people who use drugs from the national database using the definitions introduced by the WHO. Once the list is completed with patient ART codes, a consultative meeting combined with the project orientation will be convened. Providers from the selected ART clinics and implementing partners at each site will divide stable people living with HIV into their respective groups based on the ART sites.
|
Other: Community-based ART delivery (CAD)
The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months. |
|
Active Comparator: ART multi-month dispensing (MMD)
A total of 2000 registered stable people living with HIV will form into the control group and received standard services under the MDD model. The control-arm participants will visit the ART clinics and collect their ARVs from the facility-based staff.
|
Other: ART multi-month dispensing (MMD)
The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months. |
- Percent of people living with HIV with viral suppression [ Time Frame: 24 months after the intervention started ]Viral load At least 90% of participants in intervention arm will have a viral load <1000 RNA copies/mL by the endline of the intervention
- Percent of people living with HIV who remained in HIV care and treatment [ Time Frame: 24 months after the intervention started ]At least 90% of participants in the intervention will be retained in care and treatment 12 months after the treatment started
- Percent of people living with HIV with good adherence to ART [ Time Frame: 24 months after the intervention started ]At least 90% of the participants in the intervention will report good adherence to ART at the endline.
- Percent of healthcare providers at ART clinics who reported reduced workload [ Time Frame: 24 months after the intervention started ]Workload at ART clinics will be self-reported by health care workers providing ART services at the clinics. The investigators hypothesize that a significantly higher proportion of health care providers at ART clinics under the CAD intervention arm will agree that their workload has been reduced at endline compared to baseline.
- Cost-effectiveness of community-based ART delivery (CAD) model intervention [ Time Frame: 24 months after the intervention started ]For the cost-effectiveness analyses, direct and indirect medical costs for follow-up care and ARV refills will be collected. The costs in this community-based ART delivery intervention will be compared with the costs in standard care services (facility-based and multi-month dispensing model). The investigators anticipated that the community-based ART delivery intervention will be similar in all intervention and service delivery models. However, CAD model will help save time and costs of people living with HIV in the intervention arm.
- Percent of people living with HIV who reported improved quality of life [ Time Frame: 24 months after the intervention started ]The quality of life of people living with HIV will be measured using WHO's Quality of Life HIV brief questionnaire (WHOQOL-HIV-BREF). The scale's domain score ranges from 4 to 20. Higher scores indicate a better quality of life. The investigators hypothesized that the proportion of people living with HIV who reported a higher quality of life would increase more significantly from baseline to endline among participants in the community-based ART delivery (CAD) intervention arm than those in the control arm.
- Percent of people living with HIV who reported improved mental health [ Time Frame: 24 months after the intervention started ]The mental health of people living with HIV will be measured using the Center for Epidemiologic Studies Depression Scale (CES-D). The total CES-D score ranges from 0 to 60. A subject with a CES-D score of ≥16 will be defined as having depressive symptoms. The investigators hypothesized that the proportion of people living with HIV who reported having depressive symptoms would decrease more significantly from baseline to endline among participants in the community-based ART delivery (CAD) intervention arm than in the control arm.
- Percent of people living with HIV who reported improved social support health [ Time Frame: 24 months after the intervention started ]Social support for people living with HIV will be measured using Berlin Social Support Scale (BSSS). The BSSS's total score ranges from 15 to 60, with higher scores indicating higher social support. The investigators hypothesized that the proportion of people living with HIV who perceived a high social support level would increase more significantly from baseline to endline among participants in the community-based ART delivery (CAD) intervention arm than those in the control arm.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Receiving ART for at least one year.
- No adverse drug reactions or ARV drug interactions requiring regular monitoring.
- No suspected or confirmed tuberculosis, no other opportunistic infections, and not on any prophylaxis.
- Not pregnant/breastfeeding (for women).
- Having a good understanding of lifelong treatment and adherence to the medication.
- Presenting with evidence of treatment success: two consecutive undetectable viral load measures (or, in the absence of viral load monitoring, CD4 counts above 200 cells/mm3 and objective adherence measure).
- Aged ≥15 years.
- On the first-line ARV regimen.
Exclusion criteria
- Unstable people living with HIV as defined above
- Mobile populations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04766710
| Contact: Siyan Yi, PhD | 6587533823 | siyan@doctor.com | |
| Contact: Sovannary Tuot, MA | 85523211505 ext 259 | tsovannary@khana.or.kh |
| Cambodia | |
| KHANA Center for Population Health Research | Recruiting |
| Phnom Penh, Cambodia, 2361 | |
| Contact: Sok Chamreun Choub, MA +855 23 211 505 csokchamreun@khana.org.kh | |
| Contact: Sovannary Tuot, MA +855 12 836926 tsovannary@khana.org.kh | |
| Cambodia Anti-Tuberculosis Association | Recruiting |
| Phnom Penh, Cambodia, 2589-384 | |
| Contact: Ky Mom, MD +855 23 219 127 cata@thecata.org.kh | |
| Contact: Monyrath Chry, MA +85512666507 rath@thecata.org.kh | |
| National Center for Tuberculosis and Leprosy Control | Recruiting |
| Phnom Penh, Cambodia, 2589 | |
| Contact: Tan Eang Mao, MPH +855 23 219 274 mao@online.com.kh | |
| Contact: Kim Eam Khun, MPH +855 23 224 971 kimeamk@cenat.gov.kh | |
| Study Chair: | Sok Chamreun Choub, MA | KHANA Center for Population Health Research | |
| Study Chair: | Penh Sun Ly, MD | National Center for HIV, Dermatology and STD |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Siyan Yi, Assistant Professor, National University, Singapore |
| ClinicalTrials.gov Identifier: | NCT04766710 |
| Other Study ID Numbers: |
030_PV_KHANA |
| First Posted: | February 23, 2021 Key Record Dates |
| Last Update Posted: | September 1, 2021 |
| Last Verified: | August 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | The datasets used and/or analyzed during the current study will be available from the principal investigator on reasonable request. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
| Time Frame: | The data will permanently available after the main report of the project has been published. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
HIV Community-based services ART |
Operational research Intervention Cambodia |
|
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |

